Inventiva SA
Company Profile
Business description
Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.
Contact
50 rue de Dijon
Daix21121
FRAT: +33 380447500
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
77
Stocks News & Analysis
stocks
Australia’s oldest REIT undervalued
stocks
Stop asking if there’s a stock market bubble. Ask this instead.
stocks
Are negative AI narratives holding this ASX share back?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,931.40 | 71.60 | -0.80% |
| CAC 40 | 8,337.29 | 66.70 | -0.79% |
| DAX 40 | 25,040.28 | 44.47 | 0.18% |
| Dow JONES (US) | 52,305.24 | 13.96 | -0.03% |
| FTSE 100 | 10,478.34 | 18.78 | -0.18% |
| HKSE | 22,881.02 | 145.66 | -0.63% |
| NASDAQ | 26,040.03 | 173.69 | -0.66% |
| Nikkei 225 | 70,474.96 | 412.64 | 0.59% |
| NZX 50 Index | 13,609.79 | 0.71 | -0.01% |
| S&P 500 | 7,483.23 | 16.13 | -0.22% |
| S&P/ASX 200 | 8,722.90 | 71.70 | -0.82% |
| SSE Composite Index | 4,094.40 | 20.50 | 0.50% |